---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290466910.md"
description: "Altimmune shares are trading higher after Leerink Partners initiated coverage on the stock with an Outperform rating and announced a $10 price target."
datetime: "2026-06-22T17:47:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290466910.md)
  - [en](https://longbridge.com/en/news/290466910.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290466910.md)
---

# 

Altimmune shares are trading higher after Leerink Partners initiated coverage on the stock with an Outperform rating and announced a $10 price target.

### Related Stocks

- [ALT.US](https://longbridge.com/en/quote/ALT.US.md)

## Related News & Research

- [ALT: Pemvidutide met key efficacy endpoints in AUD, reducing heavy drinking and increasing abstinence](https://longbridge.com/en/news/294057380.md)
- [Altimmune's drug meets main goal of mid-stage study for alcohol use disorder](https://longbridge.com/en/news/294056614.md)
- [Altimmune’s Pemvidutide Meets Phase II Endpoint in Alcohol Use Disorder Trial](https://longbridge.com/en/news/294079208.md)
- [Altimmune reports positive Phase 2 RECLAIM topline results for pemvidutide in AUD](https://longbridge.com/en/news/294056102.md)
- [Li Bang International Announces 1-for-200 Share Consolidation | LBGJ Stock News](https://longbridge.com/en/news/294268950.md)